[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myofascial-trigger-points\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myofascial-trigger-points":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,52,76,93,109,124],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100054226","effects-of-different-myofascial-release-techniques-on-function-in-chronic-non-specific-neck-pain-100054226",false,"NCT07694882","Effects of Different Myofascial Release Techniques on Function in Chronic Non-Specific Neck Pain","Investigation of the Effects of Different Myofascial Release Techniques on Functional Outcomes in Individuals With Chronic Non-Specific Neck Pain","MFR \u002F CNNP","Inclusion Criteria:\n\n* Neck pain persisting for at least 3 months and diagnosed as chronic non-specific neck pain by a specialist physician\n* Aged between 18 and 45 years\n* Perceived pain affecting daily living activities (VAS at least 3)\n* Presence of myofascial trigger points in the upper-quarter muscles\n\nExclusion Criteria:\n\n* Specific serious cervical spine pathology (radiculopathy, myelopathy, severe nerve root compression, spondylosis, and similar)\n* History of rheumatologic, neurologic, or systemic disease (for example, acute inflammation, multiple sclerosis, Parkinson's disease, rheumatoid arthritis, fibromyalgia, or cancer)\n* History of trauma, fracture, or surgery involving the neck, shoulder, or upper extremity\n* Pregnancy or breastfeeding\n* Any diagnosed psychiatric disorder (for example, major depression or anxiety disorder) or regular use of psychopharmacological medication\n* Use of systemic analgesics, NSAIDs, or muscle relaxants within the last 7 days for pain control\n* Any physiotherapy, manual therapy, or injection treatment to the neck region within the last 3 months","ALL","18 Years","45 Years",{"count":21,"type":22},84,"ESTIMATED","INTERVENTIONAL",[25],"NA","This single-center, three-arm randomized controlled trial compares the effects of different myofascial release techniques, combined with a structured exercise program, on functional outcomes in individuals with chronic non-specific neck pain (CNNP).\n\nEligible participants (aged 18 to 45 years, neck pain for at least 3 months, pain intensity VAS at least 3, and myofascial trigger points in the upper-quarter muscles) are allocated by simple randomization into three groups:\n\n* Conventional Therapy Group: hot pack, conventional TENS, and a structured exercise program.\n* Manual Myofascial Release Group: conventional therapy plus therapist-applied manual myofascial release.\n* Self-Myofascial Release Group: conventional therapy plus supervised self-applied myofascial release using a duo-ball, balls, and a massage stick\u002Fcane.\n\nAll interventions are delivered 3 days per week for 6 weeks. The primary outcome is pain intensity. Secondary outcomes include pressure pain threshold and tolerance, cervical range of motion, muscle stiffness, craniovertebral angle, cervical proprioception, muscle strength and endurance, disability, neck awareness, multidimensional biopsychosocial status, sleep quality, quality of life, and kinesiophobia. The aim is to determine whether manual or self-applied myofascial release, added to exercise, produces greater functional improvement in people with chronic non-specific neck pain.",[28,29,30,31],"Chronic Neck Pain","Non-specific Neck Pain","Myofascial Trigger Points","Myofascial Pain Syndrome - Neck",[33,34,35,36,37,38],"chronic non-specific neck pain","myofascial release","manual therapy","trigger points","therapeutic exercise","physiotherapy","NOT_YET_RECRUITING","2026-07-10",{"date":42,"type":43},"2026-07-13","ACTUAL",{"date":45,"type":22},"2026-07-15",{"date":47,"type":22},"2026-12-31",{"name":49,"class":50},"Eastern Mediterranean University","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":51},"100619625","clinical-study-of-myofascial-trigger-pointsmtrps-injection-in-the-treatment-of-shoulder-osteoarthritisoa-100619625","NCT07347054","Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Shoulder Osteoarthritis(OA)","Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Chronic Musculoskeletal Pain(CMP), Chronic Migraine and Cervicogenic Headache","Inclusion Criteria:\n\n* Diagnosis of shoulder osteoarthritis with radiographic evidence of osteoarthritis (Kellgren-Lawrence grade 1-4) confirmed by at least two orthopedic surgeons, pain specialists, or general practitioners, with physical examination confirming at least one myofascial trigger point;\n* Disease duration exceeding 3 months;\n* Age ≥ 45 years;\n* Numerical Rating Scale (NRS) score ≥ 3 points despite prior conservative pharmacological treatment;\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* History of allergy to trial medications such as corticosteroids;\n* Alcohol abuse; long-term use of opioids (exceeding 2 weeks or more than 3 days per week for over 1 month); suspected use of sedative or analgesic medications; patients on long-term steroid therapy;\n* Severe neurological disorders, significant hepatic or renal dysfunction, heart failure, coagulation abnormalities, gastric ulcer, diabetes, inflammatory rheumatic diseases, etc.;\n* Intra-articular injection within the past 6 months or planned joint replacement surgery;\n* Inability to use pain assessment scales;\n* Presence of local or systemic infection;\n* Pregnant or lactating patients.",{"count":60,"type":22},1036,[25],"Chronic musculoskeletal pain (CMP) is a common disease in China, with a high incidence among the elderly, and has a significant impact on patients' quality of life. Shoulder osteoarthritis is a common type of CMP. Currently, both domestic and international studies have confirmed that glucocorticoid injection at myofascial trigger points(MTrPs) can alleviate patients' pain symptoms. MTrPs injection is safe and easy to operate, and can improve the clinical management efficiency of patients with shoulder osteoarthritis. Therefore, we designed a prospective, randomized controlled, blinded outcome, non-inferiority study to compare the long-term clinical efficacy of glucocorticoid injection at myofascial trigger points and complex intra-articular injection in treating shoulder osteoarthritis. Patients will be randomly divided into two groups and receive either glucocorticoid injection at MTrPs or joint cavities. After treatment, patients will be followed up for 2 years. Their NRS scores, WOMAC scores, Patient Global Impression of Change(PGIC) scale, and adverse reactions will be recorded at 2 weeks, 4 weeks, 8 weeks, 12 weeks, and 24 weeks. If the results indicate that the clinical efficacy of myofascial trigger point injection for shoulder osteoarthritis is not inferior to that of injection at intra-articular injection, it will provide a safe and simple treatment option that is easy to promote for patients who do not respond to conservative treatment.",[30,64,65],"Chronic Musculoskeletal Pain","Shoulder Osteoarthritis","RECRUITING","2026-01-11",{"date":69,"type":43},"2026-01-16",{"date":71,"type":43},"2025-12-01",{"date":73,"type":22},"2027-06-01",{"name":75,"class":50},"Beijing Tiantan Hospital",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":57,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":89,"startDateStruct":90,"completionDateStruct":91,"leadSponsor":92,"locationsCount":51},"100619677","clinical-study-of-myofascial-trigger-pointsmtrps-injection-in-the-treatment-of-chronic-cervicogenic-headache-100619677","NCT07347730","Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Chronic Cervicogenic Headache","Inclusion Criteria:\n\n* Diagnosed with cervicogenic headache by at least two pain specialists or neurologists;\n* Disease duration of at least 3 months;\n* Age between 18 and 65 years;\n* Numerical Rating Scale (NRS) score ≥ 3 despite conservative pharmacological treatment;\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* History of allergy to trial medications such as corticosteroids;\n* Alcohol abuse; long-term use of opioids (exceeding 2 weeks or more than 3 days per week for over 1 month); suspected use of sedative or analgesic medications; patients on long-term steroid therapy;\n* Severe neurological disorders, significant hepatic or renal dysfunction, heart failure, coagulation abnormalities, gastric ulcer, diabetes, inflammatory rheumatic diseases, etc.;\n* Inability to use pain assessment scales;\n* Presence of local or systemic infection;\n* Pregnant or lactating patients.","65 Years",{"count":60,"type":22},[25],"Chronic cervicogenic headache is a common disease in China, with a high incidence among the elderly, and has a significant impact on patients' quality of life. Currently, both domestic and international studies have confirmed that glucocorticoid injection at myofascial trigger points(MTrPs) can alleviate patients' pain symptoms. MTrPs injection is safe and easy to operate, and can improve the clinical management efficiency of patients with chronic cervicogenic headache. Therefore, we designed a prospective, randomized controlled, blinded outcome, non-inferiority study to compare the long-term clinical efficacy of glucocorticoid injection at myofascial trigger points and greater occipital nerve block injection in treating chronic cervicogenic headache. Patients will be randomly divided into two groups and receive either glucocorticoid injection at MTrPs or dorsal rami blocks of C2 spinal nerves. After treatment, patients will be followed up for 2 years. Their NRS scores, attack frequency, attack duration, HIT-6 scores, Patient Global Impression of Change(PGIC) scale, and adverse reactions will be recorded at 2 weeks, 4 weeks, 8 weeks, 12 weeks, and 24 weeks. If the results indicate that the clinical efficacy of myofascial trigger point injection for chronic cervicogenic headache is not inferior to that of injection at intra-articular injection, it will provide a safe and simple treatment option that is easy to promote for patients who do not respond to conservative treatment.",[30,87,88],"Cervicogenic Headache","Dorsal Root Ganglion",{"date":69,"type":43},{"date":71,"type":43},{"date":73,"type":22},{"name":75,"class":50},{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":57,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":99,"targetDuration":4,"studyType":23,"phases":100,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":105,"startDateStruct":106,"completionDateStruct":107,"leadSponsor":108,"locationsCount":51},"100619626","clinical-study-of-myofascial-trigger-pointsmtrps-injection-in-the-treatment-of-chronic-migraine-100619626","NCT07347067","Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Chronic Migraine","Inclusion Criteria:\n\n* Diagnosed with migraine by at least two pain specialists or neurologists;\n* Disease duration of at least 3 months;\n* Age between 18 and 65 years;\n* Numerical Rating Scale (NRS) score ≥ 3 despite conservative pharmacological treatment;\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* History of allergy to trial medications such as corticosteroids;\n* Alcohol abuse; long-term use of opioids (exceeding 2 weeks or more than 3 days per week for over 1 month); suspected use of sedative or analgesic medications; patients on long-term steroid therapy;\n* Severe neurological disorders, significant hepatic or renal dysfunction, heart failure, coagulation abnormalities, gastric ulcer, diabetes, inflammatory rheumatic diseases, etc.;\n* Inability to use pain assessment scales;\n* Presence of local or systemic infection;\n* Pregnant or lactating patients.",{"count":60,"type":22},[25],"Chronic migraine is a common disease in China, with a high incidence among the elderly, and has a significant impact on patients' quality of life. Currently, both domestic and international studies have confirmed that glucocorticoid injection at myofascial trigger points(MTrPs) can alleviate patients' pain symptoms. MTrPs injection is safe and easy to operate, and can improve the clinical management efficiency of patients with chronic migraine. Therefore, we designed a prospective, randomized controlled, blinded outcome, non-inferiority study to compare the long-term clinical efficacy of glucocorticoid injection at myofascial trigger points and greater occipital nerve block injection in treating chronic migraine. Patients will be randomly divided into two groups and receive either glucocorticoid injection at MTrPs or greater occipital nerve. After treatment, patients will be followed up for 2 years. Their NRS scores, attack frequency, attack duration, HIT-6 scores, Patient Global Impression of Change(PGIC) scale, and adverse reactions will be recorded at 2 weeks, 4 weeks, 8 weeks, 12 weeks, and 24 weeks. If the results indicate that the clinical efficacy of myofascial trigger point injection for chronic migraine is not inferior to that of injection at intra-articular injection, it will provide a safe and simple treatment option that is easy to promote for patients who do not respond to conservative treatment.",[30,103,104],"Chronic Migraine Headache","Greater Occipital Nerve Block",{"date":69,"type":43},{"date":71,"type":43},{"date":73,"type":22},{"name":75,"class":50},{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":57,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":116,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":120,"startDateStruct":121,"completionDateStruct":122,"leadSponsor":123,"locationsCount":51},"100619623","clinical-study-of-myofascial-trigger-pointsmtrps-injection-in-the-treatment-of-knee-osteoarthritisoa-100619623","NCT07347028","Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Knee Osteoarthritis(OA)","Inclusion Criteria:\n\n* Diagnosis of knee osteoarthritis with radiographic evidence of osteoarthritis (Kellgren-Lawrence grade 1-4) confirmed by at least two orthopedic surgeons, pain specialists, or general practitioners, with physical examination confirming at least one myofascial trigger point;\n* Disease duration exceeding 3 months;\n* Age ≥ 45 years;\n* Numerical Rating Scale (NRS) score ≥ 3 points despite prior conservative pharmacological treatment;\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* History of allergy to trial medications such as corticosteroids;\n* Alcohol abuse; long-term use of opioids (exceeding 2 weeks or more than 3 days per week for over 1 month); suspected use of sedative or analgesic medications; patients on long-term steroid therapy;\n* Severe neurological disorders, significant hepatic or renal dysfunction, heart failure, coagulation abnormalities, gastric ulcer, diabetes, inflammatory rheumatic diseases, etc.;\n* Intra-articular injection within the past 6 months or planned joint replacement surgery;\n* Inability to use pain assessment scales;\n* Presence of local or systemic infection;\n* Pregnant or lactating patients.",{"count":60,"type":22},[25],"Chronic musculoskeletal pain (CMP) is a common disease in China, with a high incidence among the elderly, and has a significant impact on patients' quality of life. Knee osteoarthritis is a common type of CMP. Currently, both domestic and international studies have confirmed that glucocorticoid injection at myofascial trigger points(MTrPs) can alleviate patients' pain symptoms. MTrPs injection is safe and easy to operate, and can improve the clinical management efficiency of patients with knee osteoarthritis. Therefore, we designed a prospective, randomized controlled, blinded outcome, non-inferiority study to compare the long-term clinical efficacy of glucocorticoid injection at myofascial trigger points and complex intra-articular injection in treating knee osteoarthritis. Patients will be randomly divided into two groups and receive either glucocorticoid injection at MTrPs or joint cavities. After treatment, patients will be followed up for 2 years. Their NRS scores, WOMAC scores, Patient Global Impression of Change(PGIC) scale, and adverse reactions will be recorded at 2 weeks, 4 weeks, 8 weeks, 12 weeks, and 24 weeks. If the results indicate that the clinical efficacy of myofascial trigger point injection for knee osteoarthritis is not inferior to that of injection at intra-articular injection, it will provide a safe and simple treatment option that is easy to promote for patients who do not respond to conservative treatment.",[30,119,87,64],"Migraine",{"date":69,"type":43},{"date":71,"type":43},{"date":73,"type":22},{"name":75,"class":50},{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":57,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":23,"phases":131,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":135,"startDateStruct":136,"completionDateStruct":137,"leadSponsor":138,"locationsCount":51},"100619624","clinical-study-of-myofascial-trigger-pointsmtrps-injection-in-the-treatment-of-hip-osteoarthritisoa-100619624","NCT07347041","Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Hip Osteoarthritis(OA)","Inclusion Criteria:\n\n* Diagnosis of hip osteoarthritis with radiographic evidence of osteoarthritis (Kellgren-Lawrence grade 1-4) confirmed by at least two orthopedic surgeons, pain specialists, or general practitioners, with physical examination confirming at least one myofascial trigger point;\n* Disease duration exceeding 3 months;\n* Age ≥ 45 years;\n* Numerical Rating Scale (NRS) score ≥ 3 points despite prior conservative pharmacological treatment;\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* History of allergy to trial medications such as corticosteroids;\n* Alcohol abuse; long-term use of opioids (exceeding 2 weeks or more than 3 days per week for over 1 month); suspected use of sedative or analgesic medications; patients on long-term steroid therapy;\n* Severe neurological disorders, significant hepatic or renal dysfunction, heart failure, coagulation abnormalities, gastric ulcer, diabetes, inflammatory rheumatic diseases, etc.;\n* Intra-articular injection within the past 6 months or planned joint replacement surgery;\n* Inability to use pain assessment scales;\n* Presence of local or systemic infection;\n* Pregnant or lactating patients.",{"count":60,"type":22},[25],"Chronic musculoskeletal pain (CMP) is a common disease in China, with a high incidence among the elderly, and has a significant impact on patients' quality of life. Hip osteoarthritis is a common type of CMP. Currently, both domestic and international studies have confirmed that glucocorticoid injection at myofascial trigger points(MTrPs) can alleviate patients' pain symptoms. MTrPs injection is safe and easy to operate, and can improve the clinical management efficiency of patients with knee osteoarthritis. Therefore, we designed a prospective, randomized controlled, blinded outcome, non-inferiority study to compare the long-term clinical efficacy of glucocorticoid injection at myofascial trigger points and complex intra-articular injection in treating hip osteoarthritis. Patients will be randomly divided into two groups and receive either glucocorticoid injection at MTrPs or joint cavities. After treatment, patients will be followed up for 2 years. Their NRS scores, WOMAC scores, Patient Global Impression of Change(PGIC) scale, and adverse reactions will be recorded at 2 weeks, 4 weeks, 8 weeks, 12 weeks, and 24 weeks. If the results indicate that the clinical efficacy of myofascial trigger point injection for knee osteoarthritis is not inferior to that of injection at intra-articular injection, it will provide a safe and simple treatment option that is easy to promote for patients who do not respond to conservative treatment.",[30,64,134],"Hip Osteoarthritis",{"date":69,"type":43},{"date":71,"type":43},{"date":73,"type":22},{"name":75,"class":50}]